INHIBRX BIOSCIENCES, INC. Basic Shares Outstanding (Weighted Average)
INHIBRX BIOSCIENCES, INC. (INBX) reported Basic Shares Outstanding (Weighted Average) of 15.67 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 15.67M shares, a 1.30% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 15.59M shares, a 0.76% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 15.54M shares, a 0.39% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 15.48M shares, a 0.06% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 15.49M shares, a 4.63% increase from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 14.80M shares, a 25.62% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 11.78M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 15.67M shares 10-Q · filed 2026-08-13 | 15.63M shares 10-Q · filed 2026-08-13 | 15.60M shares derived: average of 3 quarters · filed 2026-08-13 | 15.57M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 15.59M shares 10-Q · filed 2026-05-14 | 15.56M shares derived: average of 2 quarters · filed 2026-05-14 | 15.53M shares derived: average of 3 quarters · filed 2026-05-14 | 15.52M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 15.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 15.51M shares derived: average of 2 quarters · filed 2026-03-19 | 15.49M shares derived: average of 3 quarters · filed 2026-08-13 | 15.49M shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 15.48M shares 10-Q · filed 2025-11-14 | 15.47M shares derived: average of 2 quarters · filed 2026-08-13 | 15.47M shares 10-Q · filed 2025-11-14 | 15.47M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 15.47M shares 10-Q · filed 2026-08-13 | 15.47M shares 10-Q · filed 2026-08-13 | 15.47M shares derived: average of 3 quarters · filed 2026-08-13 | 15.47M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 15.47M shares 10-Q · filed 2026-05-14 | 15.47M shares derived: average of 2 quarters · filed 2026-05-14 | 15.47M shares derived: average of 3 quarters · filed 2026-05-14 | 15.26M shares derived: average of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | 15.47M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 15.47M shares derived: average of 2 quarters · filed 2026-03-19 | 15.19M shares derived: average of 3 quarters · filed 2026-03-19 | 14.80M shares 10-K · filed 2026-03-19 |
| 2024-09-30 | 15.47M shares 10-Q · filed 2025-11-14 | 15.04M shares derived: average of 2 quarters · filed 2025-11-14 | 14.58M shares 10-Q · filed 2025-11-14 | 14.31M shares derived: average of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | 14.62M shares 10-Q · filed 2025-08-13 | 14.13M shares 10-Q · filed 2025-08-13 | 13.93M shares derived: average of 3 quarters · filed 2025-08-13 | 13.39M shares derived: average of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 13.64M shares 10-Q · filed 2025-05-14 | 13.58M shares derived: average of 2 quarters · filed 2025-05-14 | 12.99M shares derived: average of 3 quarters · filed 2025-05-14 | 12.47M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 13.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 12.66M shares derived: average of 2 quarters · filed 2025-03-17 | 12.08M shares derived: average of 3 quarters · filed 2025-03-17 | 11.78M shares 10-K · filed 2025-03-17 |
| 2023-09-30 | 11.79M shares 10-Q · filed 2024-11-14 | 11.35M shares derived: average of 2 quarters · filed 2024-11-14 | 11.20M shares 10-Q · filed 2024-11-14 | |
| 2023-06-30 | 10.91M shares 10-Q · filed 2024-08-13 | 10.90M shares 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |